[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100536876":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":20,"centralContacts":20,"locations":20,"responsibleParty":28,"collaborators":20,"id":30,"slug":31,"hasResults":32,"nctId":33,"briefTitle":34,"officialTitle":35,"acronym":36,"eligibilityCriteria":37,"healthyVolunteers":38,"sex":39,"minAge":40,"maxAge":20,"enrollmentInfo":41,"targetDuration":20,"studyType":44,"phases":45,"briefSummary":47,"conditions":48,"keywords":20,"overallStatus":50,"whyStopped":20,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":20},{"fullName":5,"class":6},"Assistance Publique Hopitaux De Marseille","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"IgG4-RD patient","EXPERIMENTAL","Patients suffering from Immunoglobulin G4-related disease (IgG4-RD).",[13],"Procedure: Blood sampling",{"label":15,"type":10,"description":16,"interventionNames":17},"patient in remission","Patients suffering from Immunoglobulin G4-related disease (IgG4-RD) but in remission.",[13],{"label":19,"type":6,"description":20,"interventionNames":21},"healthy volunteers",null,[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":20},"PROCEDURE","Blood sampling","Blood sampling will be taken for further analysis",[9,19,15],{"type":29,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100536876","study-of-the-c5ac5ar1-axis-in-igg4-associated-disease-a-potential-therapeutic-target-100536876",false,"NCT06270524","Study of the C5a\u002FC5aR1 Axis in IgG4-associated Disease: a Potential Therapeutic Target","Pilot Study of the C5a\u002FC5aR1 Axis in IgG4-associated Disease: a Potential Therapeutic Target. C5-MAG4 Study.","C5-MAG4","Inclusion Criteria for patients suffering from IG4-related disease and patients in remission :\n\n* age \\> 18\n* diagnosis of IgG4-associated disease according to ACR\u002FEULAR 2019 classification criteria (4,5) with a score ≥20.\n* disease activity score (IgG4-RD Responder Index) ≥2 in at least one affected organ\n\nExclusion Criteria for patients suffering from IG4-related disease and patients in remission :\n\n* presence of a differential diagnosis (\"IgG4-RD mimicker\") or exclusion criterion according to ACR\u002FEULAR 2019 classification criteria (4,5).\n* systemic corticosteroid treatment ≥5 mg\u002Fday ongoing or \\\u003C 1 month ; Study C5-MAG4\\_RCAPHM21\\_0433 Protocol Version 1.1 of 16\u002F01\u002F2024 Page 15 of 41\n* immunosuppressive therapy ongoing or \\\u003C 3 months ;\n* current biotherapy treatment or \\\u003C 6 months;\n* absence of signed informed consent;\n* absence of affiliation to a Social Security scheme.\n* patient participating in an ongoing therapeutic trial ;\n* any condition which, in the opinion of the investigator, could influence the results of the study.\n\nInclusion criteria for healthy volunteers :\n\n\\- age \\> 18\n\nExclusion criteria for healthy volunteers :\n\n* infectious episode (temperature \\>38°C, flu-like signs) in the 30 days prior to inclusion;\n* known inflammatory (including IG4-related disease) or autoimmune pathology;\n* treatment with corticosteroids in progress or taken in the month prior to sampling, or immunosuppressants in progress or taken in the 3 months prior to sampling, or biotherapy in the 6 months prior to sampling;\n* absence of signed informed consent;\n* absence of affiliation to a Social Security scheme;\n* persons taking part in an ongoing therapeutic trial;\n* any condition which, in the opinion of the investigator, could influence the results of the study.",true,"ALL","18 Years",{"count":42,"type":43},66,"ESTIMATED","INTERVENTIONAL",[46],"NA","This is a monocentric, comparative, cross-sectional, case-control study seeking to identify abnormalities of the C5a-C5aR1 axis between a population of patients with active IgG4-associated disease (MAG4) and two control groups: healthy subjects without MAG4 and patients with MAG4 in remission.",[49],"Immunoglobulin G4-Related Disease","NOT_YET_RECRUITING","2024-06-25",{"date":53,"type":54},"2024-06-26","ACTUAL",{"date":56,"type":43},"2024-09-01",{"date":58,"type":43},"2027-04-30",{"name":5,"class":6}]